您当前的位置：
首页 >
文章列表页 >
Corrigendum to “A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis” [Genes & Diseases 11 (2024) 479–494]
Erratum | 更新时间：2024-02-04

    • Corrigendum to “A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis” [Genes & Diseases 11 (2024) 479–494]

    • Genes & Diseases   Vol. 11, Issue 3, (2024)
    • 作者机构：

      1. School of Pharmaceutical Science, Wenzhou Medical University,Wenzhou,China,325035

      2. Zhejiang Lab for Regenerative Medicine, Oujiang Laboratory,Wenzhou,China,325035

      3. Department of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine,Wenzhou,China,325000

      4. College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea

    • DOI：10.1016/j.gendis.2023.101168    

      CLC：

    • Published：2024，

      Published Online：1 May 2024，

    扫 描 看 全 文

  • Yanran Bi, Ruiling Zheng, Jiahao Hu, et al. Corrigendum to “A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis” [Genes & Diseases 11 (2024) 479–494]. [J]. Genes & Diseases 11(3).(2024) DOI： 10.1016/j.gendis.2023.101168.

  •  
  •  
查看原文

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

No data

Related Institution

No data
0